Payment overview · 2025
General Payments
$748.34
30 reported records · 9 companies
Healthcare provider profile · identity verified
Jarrett Gillette, MD
Allopathic & Osteopathic Physicians|Family Medicine · PORT CHARLOTTE, FL · NPI 1417362740
Verified facts
What the public records show
CMS Open Payments records show Jarrett Gillette, MD received $748.34 in general payments during 2025 across 30 reported records.
Amgen Inc. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $208.28 | 27.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.98 | 21.2% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $124.46 | 16.6% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $84.94 | 11.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $53.33 | 7.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.50 | 6.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.86 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.67 | 3.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.32 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $748.34 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $131.49 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.24 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $113.89 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $113.89 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $94.39 | 4 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $84.94 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $53.33 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.50 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 700 | 204 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 415 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 116 |
| Lisinopril | Lisinopril | 373 | 108 |
| Simvastatin | Simvastatin | 288 | 75 |
| Trazodone Hcl | Trazodone Hcl | 263 | 76 |
| Losartan Potassium | Losartan Potassium | 258 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 80 |
| Metformin Hcl | Metformin Hcl | 253 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 73 |
| Omeprazole | Omeprazole | 225 | 67 |
| Meloxicam | Meloxicam | 222 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 69 |
| Allopurinol | Allopurinol | 160 | 44 |
| Furosemide | Furosemide | 146 | 46 |
| Gabapentin | Gabapentin | 142 | 44 |
| Glipizide Er | Glipizide | 141 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 43 |
| Alprazolam | Alprazolam | 136 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 35 |
| Montelukast Sodium | Montelukast Sodium | 127 | 43 |
| Ozempic | Semaglutide | 125 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 33 |
| Prednisone | Prednisone | 112 | 89 |
| Sertraline Hcl | Sertraline Hcl | 104 | 29 |
| Azithromycin | Azithromycin | 103 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 36 |
| Finasteride | Finasteride | 99 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 33 |
| Eliquis | Apixaban | 98 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 89 | 29 |
| Ezetimibe | Ezetimibe | 87 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 24 |
| Carvedilol | Carvedilol | 76 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 74 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 24 |
| Clonazepam | Clonazepam | 71 | 18 |
| Jardiance | Empagliflozin | 69 | 23 |
| Potassium Chloride | Potassium Chloride | 68 | 18 |
| Azelastine Hcl | Azelastine Hcl | 64 | 36 |
| Famotidine | Famotidine | 63 | 22 |
| Irbesartan | Irbesartan | 62 | 16 |
| Tramadol Hcl | Tramadol Hcl | 62 | 28 |
| Atenolol | Atenolol | 59 | 17 |
| Valacyclovir | Valacyclovir Hcl | 58 | 22 |
| Valsartan | Valsartan | 49 | 12 |
| Lovastatin | Lovastatin | 48 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Fenofibrate | Fenofibrate | 46 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 42 |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Spironolactone | Spironolactone | 42 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 15 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 11 |
| Xarelto | Rivaroxaban | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 19 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 24 |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Nabumetone | Nabumetone | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | 14 |
| Naproxen | Naproxen | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Sucralfate | Sucralfate | 22 | 11 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Topiramate | Topiramate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $748.34 · 30 records | Amgen Inc. | AIRSUPRA, Da Vinci Surgical System, EVENITY, Korlym, Leqembi, MOUNJARO, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error